Bristol-Myers Squibb - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Bristol-Myers Squibb

Top of Directory » All Categories » by Company » Bristol-Myers Squibb



  • Safety and Efficacy of BMS-790052 Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2b and Ribavirin)

    Condition:   Hepatitis C Infection
    Interventions:   Drug: BMS-790052;   Drug: BMS-790052;   Drug: Placebo;   Drug: Peginterferon alfa-2b;   Drug: Ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Safety and Efficacy of BMS-790052 Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

    Condition:   Hepatitis C Infection
    Interventions:   Drug: BMS-790052;   Drug: BMS-790052;   Drug: Placebo;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Functional Neuroimaging of Postural Reconstruction

    Condition:   Healthy
    Intervention:   Radiation: SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging
    Sponsor:   University Hospital, Strasbourg, France
    Recruiting - verified November 2009
  • Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: BMS-790052;   Drug: BMS-650032;   Drug: pegylated-interferon-α;   Drug: ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1

    Condition:   HIV-1 Infections
    Intervention:   Drug: BMS-663068 with or without ritonavir
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

    Conditions:   Breast Cancer;   Lung Cancer;   Colon Cancer;   Pancreatic Cancer;   Head and Neck Cancer;   Kidney Cancer;   Sarcoma;   Hepatocellular Cancer
    Interventions:   Drug: Pazopanib;   Drug: Pazopanib;   Drug: Ixabepilone;   Drug: Ixabepilone;   Drug: Ixabepilone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   GlaxoSmithKline;   Bristol-Myers Squibb
    Recruiting - verified November 2009
  • Drug-Drug Interaction Study With Rifampin

    Condition:   Alzheimer Disease
    Interventions:   Drug: BMS-708163;   Drug: Rifampin;   Drug: Rifampin
    Sponsors:   Bristol-Myers Squibb;   PRA International
    Not yet recruiting - verified October 2009
  • Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

    Condition:   Type 2 Diabetes Mellitus (T2DM)
    Interventions:   Drug: Dapagliflozin;   Drug: Metformin XR;   Drug: Glucophage
    Sponsors:   Bristol-Myers Squibb;   AstraZeneca
    Not yet recruiting - verified October 2009
  • Efficacy, Pharmacokinetics, Safety and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japan

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Abatacept;   Drug: Abatacept;   Drug: Abatacept;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Saxagliptin;   Drug: Metformin
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb
    Recruiting - verified November 2009
  • Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Saxagliptin;   Drug: Glimepiride
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb
    Recruiting - verified November 2009
  • Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

    Condition:   Chronic Hepatitis C Virus Infection
    Interventions:   Drug: PEG-rIL-29;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
    Sponsors:   ZymoGenetics;   Bristol-Myers Squibb
    Recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials